CTI Life Sciences Fund is a venture capital firm in Canada that focuses on pharmaceutical development. Founded 2006 in Montréal, Quebec, Canada, it invests in series A, series B, series C, and venture rounds. Its portfolio companies include Visterra, PreciThera, PHEMI Health Systems, SutroVax, CellAegis Devices, ILKOS Therapeutic, IMV Inc, DalCor Pharmaceuticals, and Zymeworks. As of February 2020, CTI Life Sciences Fund has made 23 investments. Their most recent investment was on October 5, 2017, when Visterra raised $23.6M. CTI Life Sciences Fund has had seven exits, the most notable of which include Zymeworks, Visterra, and Medicago. The company has raised two funds, their latest being CTI Life Sciences Fund II. This fund was announced on January 15, 2015 and raised a total of $134M.